Down-regulation of hepatic AMP-activated protein kinase and up-regulation of CREB coactivator CRTC2 for gluconeogenesis under calorie-restricted conditions at a young age by Trindade Lucas Siqueira et al.
Acta Med. Nagasaki 55: 85−92−
Introduction
　AMP-activated protein kinase (AMPK) is a cellular en-
ergy sensor that responds immediately to a reduction of 
ATP1. AMPK also regulates whole body energy metabolism 
particularly through adipokines such as adiponectin, leptin, 
and ghrelin on a long-term basis2. AMPK suppresses he-
patic fatty acid and cholesterol synthesis while activating 
fatty acid oxidation3. AMPK also represses hepatic gluco-
neogenesis. In the skeletal muscle, AMPK enhances glucose 
uptake through upregulation of membrane translocation of 
glucose transporter 4 and also augments fatty acid oxida-
tion3. In the white adipose tissue, AMPK suppresses fatty 
acid synthesis and lipolysis3. These effects of AMPK are 
expected to totally reduce blood glucose, serum insulin and 
IGF-1 levels as does CR and thus chronic activation of 
AMPK is considered to be a pro-longevity strategy4.
　Current studies have indicated a possible involvement of 
AMPK signal pathways in the regulation of aging and 
lifespan in organisms. Activation of AMPK signaling ex-
tends lifespan in C. elegans5,6. AMPK suppresses the target 
of rapamycin (TOR) signaling3; abrogation of TOR signal-
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ing also increases lifespan in C. elegans7. Deletion of ribo-
somal protein S6 kinase 1 (S6K1), a component of the mam-
malian TOR (mTOR) signal pathway, is also reported to 
extend the lifespan in mice, though only in female mice8. 
Deletion of S6K1 induced gene expression patterns similar 
to those seen in CR or with pharmacological activation of 
AMPK in the liver and skeletal muscle8. Therefore, one 
might speculate that CR affects aging and lifespan partly 
through activation of AMPK and thus suppression of the 
mTOR pathway in multiple organs.
　However, the effect of CR on AMPK has been controver-
sial even in cases where a specified organ was studied. In 
the liver, we reported a decrease in the threonine-172-phos-
phorylated (p) AMPKa level (hence the active form) in CR 
rats9. However, other laboratories have reported similar lev-
els between CR and control groups10 or even up-regulation 
of the p-AMPK levels in CR rats11.
　The present study evaluated the effect of CR on down-
stream molecules of AMPK, a transducer of regulated 
CREB activity 2 (CRTC2; formerly TORC2) and mTOR in 
the liver to resolve the reported contradictions. CRTC2 is a 
transcriptional regulator that promotes translation of the 
PPAR gamma coactivator-1α (PGC-1α) gene in concert with 
the cAMP responsive element binding protein (CREB) for 
induction of gluconeogenic enzyme genes12. Insulin and 
AMPK phosphorylate CRTC2 and exclude it from the nu-
cleus, leading to attenuation of gluconeogenesis. We fo-
cused on the liver in the present study because the liver is a 
critical energy converter that supplies energy to other or-
gans in concert with the white adipose tissue. Studies sug-
gesting the relation between up-regulation of AMPK and 
longevity or an anti-neoplastic effect of CR have confirmed 
the findings in the rodent liver8,11,13. The present results sup-
port the downregulation of hepatic AMPK activity by CR. 
We discuss the role of AMPK in the metabolic adaptation to 
long-term CR.
Materials and methods 
Experimental animals and tissues
　All experiments in the present study were performed in 
accordance with the provisions of the Ethics Review Com-
mittee for Animal Experimentation at Nagasaki University. 
The experimental animals and procedures were reported 
elsewhere14,15. Briefly, male Fischer 344 rats (F344/DuCrj), 
certified to be specific pathogen-free, were purchased from 
Charles River Laboratory Japan (Yokohama, Japan). Rats 
were housed separately in a barrier facility (temperature 21-
24°C; 12 hour/12 hour-light/ dark cycle) at an animal facility 
at the Biomedical Research Center of Nagasaki University. 
Rats fed ad libitum (AL) until 2.5 months (young) and 18 
months (middle-age) of age were randomly assigned to the 
control AL group or the calorie restricted (CR) group. The 
young- and middle-age-AL groups continued to receive 
food AL; the CR groups received 30% less food than the 
respective AL groups by a modified alternate-day feeding 
program. The CR groups received two lots of 30% less food 
every other day, 30 min before lights were turned off. Food 
intakes in the AL groups were monitored every 2 weeks and 
the amounts of food given to the CR groups were adjusted 
accordingly.
　At 7 and 22 months of age, when rats were subjected to 
glucose tolerance tests, the CR groups had 24% and 28% 
lower body weights as compared to the age-matched AL 
groups14. The results indicating that CR improved glucose 
tolerance at both ages were reported elsewhere14. With an 
interval of 2 or more weeks after GTT, rats were fasted 
overnight and sacrificed 15 min after an intraperitoneal in-
jection of D-glucose (1.0 g/kg body weight; 50% solution) or 
saline to evaluate the glucose-stimulated insulin response 
and subsequent activation of insulin- and/ or glucose-relat-
ed signal molecules. Liver tissue was collected immediately, 
weighed, quickly diced, and frozen in liquid nitrogen. 
　The blood glucose and serum insulin concentrations in 
this experimental setting were reported elsewhere14. The 
data indicated that glucose-stimulated serum insulin re-
sponse was lower in the CR groups as compared to the AL 
groups. However, the phosphorylated Akt1 level, an index 
of activation of insulin signaling, was greater in the glu-
cose-injected CR group than in the glucose injected AL 
group at 7 mo, suggesting sensitization of insulin signaling 
in the liver of CR group (Supplemental data).
Tissue preparation for Western blotting
 
　For analysis of p-AMPKα (Thr-172) and p-mTOR, the cy-
tosolic fractions were isolated from frozen liver and skeletal 
muscle tissues according to the polyethylene glycol (PEG) 
precipitation method16. Briefly, frozen tissues (200–250 mg) 
were homogenized in a homogenization buffer consisting of 
50 mM Tris–HCl (pH 7.7 at 4°C), 50 mM NaF, 5 mM sodium 
pyrophosphate, 1 mM EDTA, 1 mM EGTA, 0.25 M mannitol, 
1 mM dithiothreitol (DTT) and the following protein inhibi-
tors: 1 mM phenylmethylsulfonyl fluoride (PMSF), 4μM soy-
bean trypsin inhibitor and 1 mM benzamidine. After ho-
mogenization for 40 s at 4°C, the mixture was centrifuged at 
14,000g for 20 min at 4°C. The resulting supernatant was 
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mixed with a final concentration of 2.5% PEG, vortexed for 
10 min and centrifuged at 10,000g for 10 min at 4°C. The 
resulting supernatant was resuspended in a buffer consist-
ing of 100 mM Tris–HCl (pH 7.5 at 4°C), 50 mM NaF, 5 
mM sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 
10% glycerol, 1 mM DTT, 0.02% sodium azide and the fol-
lowing protein inhibitors: 1 mM PMSF, 4μM soybean 
trypsin inhibitor and 1 mM benzamidine. 
　For analysis of CREB, total tissue lysates were prepared 
using lysis buffer [50 mM Tris–HCl at pH 7.4, 50 mM so-
dium pyrophosphate, 5 mM sodium orthovanadate, 50 mM 
NaF, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 5 mg/mL aprotinin, 2 mg/mL leupeptin, 1% Triton 
X-100]. Homogenates were centrifuged (10,000g, 20 min, 
4°C) and the supernatant was collected. The protein content 
of the lysates was determined using the bicinchoninic acid 
(BCA) protein assay kit (Pierce Biotechnology, Rockford, 
IL). 
Preparation of hepatic nuclear fraction
　Livers (0.2 g) were homogenized (buffer) for 30 sec in 1.2 
mL of 10 mM HEPES-NaOH buffer (pH 7.8) containing 10 
mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 2 μg of leu-
peptin per mL, 1 μg of pepstatin per mL, 5 μg of aprotinin 
per mL, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mM 
Na3VO4. Incubated on ice for 20 min, then homogenized 
with 150 μL of homogenized buffer with 10% NP-40 for 15 
sec. The homogenate was carefully layered onto 5 mL of the 
same buffer in a centrifuge tube, followed by centrifugation 
at 12,000 rpm and 4°C for 2 min. The precipitate was washed 
twice with homogenized buffer with 1% NP-40 followed by 
centrifugation at 12,000 rpm and 4°C for 30 sec. The pre-
cipitate was resuspended in 100 μL (50 mM HEPES-NaOH 
buffer [pH 7.8] containing 50 mM KCl, 3 mM NaCl, 10% 
glycerol, 0.1 mM EDTA, 1 mM dithiothreitol, 2 μg of leu-
peptin per mL, 1 μg of pepstatin per mL, 5 μg of aprotinin 
per mL, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mM 
Na3VO4). The homogenate was incubated at 4°C for 30 min 
with gentle shaking each 5 min. The supernatant of the cen-
trifugation at 12,000 rpm for 10 min was stored at –80°C. 
The protein content of the lysates was determined using the 
bicinchoninic acid (BCA) protein assay kit (Pierce Biotech-
nology, Rockford, IL). 
Western blotting
　The following antibodies were used in this study; anti-p 
(Thr172)-AMPKα anti-CREB, anti-mTOR, and anti-p (Ser 
2448)-mTOR (Cell Signaling Technology, Beverly, USA), 
anti-CRCT2 (Santa Cruz Biotechnology, California, USA), 
and anti-pan AMPK (Upstate Biotechnology Inc., Lake 
Placid, NY); Enhanced chemiluminescence (ECL) Western 
blotting detection reagents and ECL-anti-rabbit or mouse 
IgG, horseradish peroxidase-linked species-specific anti-
bodies were purchased from Amersham Pharmacia Biotech 
(Little Chalfont, UK). All the dilutions were performed ac-
cording to the manufacturer's protocol. All other chemicals 
were obtained from Sigma Chemical Co. (Missouri, USA). 
All samples were boiled for 3 min and chilled on ice. Sam-
ples were diluted in protein sample buffer, and 40 μg of pro-
tein from the liver was loaded onto 7.5% SDS–polyacrylam-
ide mini-gels. Samples were resolved by electrophoresis and 
transferred to polyvinylidene difluoride membranes. The 
membranes were immediately placed in blocking solution 
(containing 0.1% Tween, 5% BSA in TBS-T buffer) for 30 
min and incubated with the primary antibody (2.5% BSA in 
TBS-T buffer) 4°C overnight. The membranes were washed 
and followed by the secondary antibody recommended by 
the manufacturer for 1 h at room temperature. Antibody la-
beling was detected using an ECL kit in accordance with 
the manufacturerʼs instructions. Specific signals were quan-
tified by Fluorchem (DE500-5T, Alpha Innotech Corpora-
tion, San Leandro, CA) with associated image analysis soft-
ware (AlphaEase FC, Alpha Innotech Corporation). To 
minimize the variance in signal intensity between the blots, 
a standard sample prepared from a mix of all tissues was 
included in each blot. Immunoblotting for β-actin was also 
performed to confirm the quality and quantity of loaded 
samples (data not shown).
Immunoprecipitation (IP)
　Nuclear extracts (4 mg) were diluted in 1 mL IP buffer 
(40 mM Tris-HCl – pH 7.6, 5mM EDTA, 120 mM NaCl, 
0.1% NP-40, 1 mM PMSF, 2 μg/mL leupeptin, 1 μg/mL 
aprotinin, 20 mM NaF, 2 mM Na3VO4), centrifuged at 
15,000 rpm at 4°C for 30 min and transferred to a new tube. 
One milligram of anti-CREB was incubated overnight at 
4°C with rotation followed by the addition of protein G-aga-
rose beads (20 μl of 50% slurry) (Upstate, California, USA) 
and rotating at 4°C overnight. The immunoprecipitates were 
washed three times sequentially with IP buffer and a West-
ern blot for CRCT2 was performed.17 
RT-PCR
　Total RNA was extracted as previously described18. The 
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quality of extracted RNA was evaluated as the densitomet-
ric ratio of 28S and 16S ribosomal RNA. The extracted 
RNA was reverse-transcribed using a Bio-Rad reverse tran-
scriptase reagent kit (Hercules, USA) according to the man-
ufacturerʼs protocol, and real-time PCR was performed as 
previously described19 using primers and probes for PEPCK, 
PGC-1 and β-actin (Applied Biosystems, Tokyo, Japan). The 
sequences of the primers and TaqMan probes were as fol-
lows: PEPCK: sense, 50-TCCGGGCACCTCAGTGAA-30; 
antisense, 50-ACGTTGGTGAAGATGGTGTTTTT-30; Taq-
Man probe, 50-FAM-CGCCATTAAGACCATC-TA MRA-
30; β-actin: sense, 50-ACTGCCCTGGCTCCTAGCA-30; 
antisense, 50-GAGCCACCAATCCACACAGA-30; TaqMan 
probe, 50-FAM-ATCAAGATCATTGCTCCTCCTGAGCGC-
TAMRA-30. The results were normalized for β-actin ex-
pression levels in all samples; the expression levels of 
β-actin were confirmed to be equivalent among the groups 
examined (data not shown). All samples and standard curves 
were tested in triplicate.
Statistical analysis
　Data are expressed as means ± standard deviation (SD). 
Data were analyzed by three-factor ANOVA with the main 
effects of age, diet, and glucose injection. Data were also 
analyzed by one-factor ANOVA with a post hoc test (Fish-
erʼs protected LSD test) for multiple comparisons). The level 
of significance was set at p < 0.05.
Results
AMPK levels
　The protein abundance of AMPK did not differ between 
the age groups or between the diet groups (Figure 1A). The 
levels in the glucose-injected groups were also not different 
from those in the saline groups. The Thr172-phosphorylated 
(p-) AMPK levels were lower in the middle-aged groups 
than in the young groups, particularly in the AL groups 
(Age, p = 0.0051; Age x Diet, p = 0.0870; Figure 1B). The 
p-AMPK levels did not differ between the glucose- and sa-
line-injected groups. When the data were decomposed by 
age, the p-AMPK levels were lower in the CR groups at the 
young age (Diet, p = 0.002) and there was no difference at 
the middle age.
CRTC2 and CREB levels and their interaction for gluco-
neogenesis
　The CRTC 2 protein abundance in the hepatic nuclear 
fraction was significantly greater in the CR groups (Diet, p 
= 0.0007; Figure 2), particularly at the young age (Diet 
⊗Age, p = 0.0730; Age = 0.0752; see also the results for mul-
tiple comparisons). The levels of CRTC2 in the glucose 
groups did not differ from those in the saline groups. 
　The interaction of CRTC2 and CREB was confirmed by 
coimmunoprecipitation and immunoblotting using samples 
from young saline-injected animals (Figure 3). To confirm 
Figure 1. Effects of calorie restriction (CR) on the level of abun-
dance of AMPKα protein (A) and threonine-172-phosphorylated 
(p)-AMPKα (B) in the liver of 7- and 22-month-old (mo) rats. 
Representative immunoblots are shown. Data are means ± SD (n 
= 5 in each group, except n = 3 for the 22 mo CR group). Within 
a panel, different letters indicate statistical differences at p < 0.05, 
as determined by one-factor ANOVA with a post hoc test.
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the role for the transcriptional complex in gluconeogenesis, 
we measured the expression levels of PGC-1α and PEPCK 
mRNA. In parallel with the findings of CRTC2 and CREB, 
the expression levels of PGC-1α and PEPCK mRNA were 
marginally or significantly greater in the CR groups than in 
the AL groups (Diet, p = 0.087 and p = 0.010 respectively; 
Figure 4A, B).
mTOR levels
　The protein abundance of mTOR did not differ between the 
groups by age, diet, and glucose or saline-injection (Figure 
5A). The p-mTOR levels were greater in the glucose-inject-
ed groups than in the saline groups (Glucose, p < 0.0001; 
Figure 5B). There was no significant difference in p-mTOR 
levels between the age groups or between the diet groups.
Figure 2. Effects of calorie restriction (CR) on the level of abun-
dance of CRTC2 protein in the hepatic nuclear fractions of 7- and 
22-month-old (mo) rats. Representative immunoblots are shown. 
Data are means ± SD (n = 5 in each group, except n = 3 for the 
22 mo CR group). Within a panel, different letters indicate statisti-
cal differences at p < 0.05, as determined by one-factor ANOVA 
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Figure 3. Effects of calorie restriction (CR) on binding of CREB 
and CRTC2 in the hepatic nuclear fraction of 7-month-old (mo) 
rats. Representative coimmunoprecipitations are shown. Data 
are means ± SD (n = 5 in each group). Different letters indicate 
statistical differences at p < 0.01, as determined by one-factor 
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Figure 4. Effects of calorie restriction (CR) on mRNA expression 
levels of PGC-1α (A) and PEPCK (B) in the liver of 7-month-old 
(mo) rats. Data are means ± SD (n = 5 in each group). Within a 
panel, different letters indicate statistical differences at p < 0.05, 
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Discussion
　The present study demonstrated that CR initiated at the 
young age in rats modestly reduced the hepatic p-AMPK 
level thus suggesting the decreased activity of AMPK by 
CR. CR initiated at the middle age did not further decrease 
the p-AMPK level, although the AL group showed an ag-
ing-related reduction of p-AMPK. Concomitantly, the nu-
clear CRTC2 level was greater in the CR group, particularly 
at the young age. The present study also confirmed the bind-
ing between CRTC2 and CREB and the up-regulation of 
gluconeogenic genes. Because AMPK represses hepatic 
gluconeogenesis partly by excluding CRTC2 from the nu-
cleus by phosphorylation12, the present data suggest that CR 
induces a physiological milieu where the gluconeogenic 
program is immediately induced in response to fasting and 
thus reduced blood glucose. From an evolutional viewpoint, 
the enhanced gluconeogenic response is also likely to cope 
with famine.
　The present study showed that CR did not affect the total 
or p-mTOR level, even though the hepatic p-AMPK level 
was reduced. The p-mTOR level acutely responded to glu-
cose load and thus activation of insulin signaling as indi-
cated by an increment of pAkt1 levels in both AL and CR 
groups (Supplemental data). Thus, at least in the liver, CR 
did not seem to regulate mTOR on a long-term basis. mTOR 
forms two complexes in cells, mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2). mTORC1, which is com-
posed of mTOR, Raptor, and mLST8 proteins, regulates cell 
growth and energy metabolism20. AMPK negatively regu-
lates mTORC1. Thus, further analyses will be necessary for 
understanding an implication of the mTORC1 pathway on 
the effect of CR, because recent studies have indicated the 
importance of mTOR signaling in the regulation of lifespan 
as well as tumorigenesis8,11,21,22.
　Long-term activation of hepatic AMPK by overexpres-
sion of a constitutively active form of AMPK-α1 represses 
Srebp-1c and its target-genes, lipogenic genes including 
fatty acid synthesis, which in turn decreases fat storage in 
the white adipose tissue23. By contrast, deletion of hepatic 
LKB1 and thus attenuated AMPK activity upregulates lipo-
genic genes more significantly under feeding conditions24. 
Thus, hepatic AMPK is also considered as a repressor for 
lipogenesis. Our previous study has demonstrated that one 
of the lipogenic genes, acetyl-CoA carboxylase 1 mRNA, 
was greatly upregulated in the fed phase of CR as compared 
to the AL phase9. Therefore, the down-regulated hepatic 
AMPK by CR could also contribute to rapid induction of 
lipogenic enzyme genes in response to energy influx.
　Our previous study in the white adipose tissue in the 
same experimental setting demonstrated that CR promotes 
lipogenesis even in the fasted condition when lipolysis is 
activated15. In this condition, the p-AMPK level was con-
sistently up-regulated in the CR group, although the level 
was only increased after glucose load and thus activation of 
insulin signaling in the AL group. AMPK is reported to re-
press lipolysis by a negative feedback loop mechanism when 
lipolysis is activated25. AMPK inhibits hormone-sensitive 
lipase (HSL) by phosphorylation26. Indeed, our preliminary 
data suggest a modest reduction of the p-HSL level at the 
young age although statistically insignificant15 (supplemen-
tal data). Thus, under CR conditions, AMPK seems to act as 
a repressor for lipolysis to limit excess loss of fat storage in 
the white adipose tissue.
　In summary, our studies suggest that CR sensitizes hepatic 
gluconeogenic and lipogenic responses in the fasted-and-fed 
cycle of food availability through consistent down-regulation 
of AMPK. By contrast, in the white adipose tissue, AMPK 
seems to act as a repressor for excess energy loss under CR 
conditions. Thus, our data implies that AMPK coordinates 
energy flux between the liver and adipose tissues under CR 
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Figure 5. Effects of calorie restriction (CR) on the level of abun-
dance of mTOR (A) and phosphorylated (p)-mTOR (B) in the 
liver of 7- and 22-month-old rats. Representative immunoblots are 
shown. Data are means ± SD (n = 5 in each group, except for n = 
3 for the 22 mo CR group). Within a panel, different letters indi-
cate statistical differences at p < 0.05, as determined by one-factor 
ANOVA with a post hoc test.
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Table 1. Glucose-stimulated serum insulin response
















 2.79 ± 0.75c




 2.03 ± 0.47c




 1.24 ± 0.10c
 4.24 ± 3.10b
Blood glucose concentrations and serum insulin concentrations were measured at 15 min after saline or glucose injection. Within 
a panel, different letters indicate statistical differences at p < 0.05, as determined by one-factor ANOVA with a post hoc test. The 
data are previously published elsewhere14.
Supplemental Figure 1. Effects of calorie restriction (CR) on the level of abundance of p-AKT1 (A), p-AKT2 (B), in the liver 
of 7-month-old (mo) rats.. Representative immunoblots are shown. Data are means + SD (n = 5 in each group). Within a panel, 
bars with common letters above them do not differ significantly, P > 0.05. as determined by one-factor ANOVA with a post hoc 
test. The antibodies to p-AKT1 and p-AKT2 were purchased from Cell Signaling Technology (Beverlym MA). Western Blots 
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